Trials / Completed
CompletedNCT06024915
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
A Phase I Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 tablets | TQ05105 is a Janus kinase 2 (JAK2) inhibitor. |
| DRUG | Itraconazole capsule | Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A). |
| DRUG | Rifampicin Capsule | Rifampicin is a strong inducer of CYP3A. |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2024-01-29
- Completion
- 2024-05-06
- First posted
- 2023-09-06
- Last updated
- 2025-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06024915. Inclusion in this directory is not an endorsement.